SHP-77 Cells
USD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The SHP-77 cell line is a human small-cell lung carcinoma (SCLC) model. It was derived from a primary lung tumor and is used extensively in cancer research, particularly for studies focused on lung cancer biology and drug development. SHP-77 cells exhibit the classic characteristics of SCLC, including rapid growth and high tumorigenic potential in xenograft models. This cell line is known for its ability to proliferate in serum-supplemented culture media and has been utilized in various experimental setups, such as studies of oncogenic signaling pathways and therapeutic response to chemotherapeutic agents. SHP-77 cells are part of the Cancer Cell Line Encyclopedia (CCLE), a resource that enables researchers to correlate genetic profiles with drug sensitivities. Genomic profiling of SHP-77 has revealed mutations and alterations in critical oncogenes and tumor suppressors, providing a platform for studying the molecular mechanisms underlying SCLC pathogenesis. The cell line has also been included in drug screening studies, offering insights into its pharmacological vulnerabilities and aiding in the identification of compounds with therapeutic potential for lung cancer. |
|---|---|
| Organism | Human |
| Tissue | Lung, left upper lobe |
| Disease | small cell carcinoma |
| Applications | 3D cell culture, Cancer research |
| Synonyms | SHP77, Shadyside Hospital Pittsburgh-77 |
Characteristics
| Age | 54 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Round cells |
| Cell type | Epithelial cells |
| Growth properties | Mixed: suspension with some loosely adherent cells |
Regulatory Data
| Citation | SHP-77 (Cytion catalog number 305498) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1693 |
Biomolecular Data
| Antigen expression | Blood Type O; Rh +; CD56; CD57 (HNK-1,Leu-7) |
|---|---|
| Tumorigenic | Yes; Yes, the cells form tumors in athymic nude mice, and usually grow as circumscribed nodules without evidence of metastases |
| Mutational profile | Mutation: ABL1, Simple, p.Val1128Glu (c.3383T>A), Zygosity=Heterozygous; Mutation: KRAS, Simple, p.Gly12Val (c.35G>T), Homozygous; Mutation: RAC1, Simple, p.Tyr32Cys (c.95A>G), Heterozygous; Mutation: TP53, Simple, p.Cys176Trp (c.528C>G), Homozygous |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Doubling time | 85 hours |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305498-260126 | Certificate of Analysis | 20. Feb. 2026 | 305498 |
| 305498-140425 | Certificate of Analysis | 18. Aug. 2025 | 305498 |